[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ureteral-stricture\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ureteral-stricture":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,75,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100594520","evaluation-of-optilume-drug-coated-balloon-for-the-endoscopic-treatment-of-ureteric-strictures-100594520",false,"NCT07020520","EvaluatioN of Optilume Drug-Coated Balloon for the Endoscopic Treatment of UREteric Strictures","ENDURE1","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Single lesion ureteric or uretero-enteric stricture less than or equal to 4.0 cm in length\n3. Two functioning kidneys\n\nExclusion Criteria:\n\n1. Treatment of the target ureter with incision or balloon dilation within 3 months of the study treatment\n2. Subjects with more than one ureteric stricture\n3. Subjects with target stricture in bifid or duplicated ureter\n4. Known sensitivity to paclitaxel or on medication that may have negative interaction with paclitaxel\n5. Ureteric stricture caused by extrinsic compression of the ureter\n6. Unable to endoscopically access target stricture for any reason\n7. Existing stones in the ipsilateral kidney or ureter (except for asymptomatic kidney stones) that are in close proximity to the target ureteric stricture\n8. Chronic renal failure treated with dialysis\n9. eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2\n10. Kidney function ≤ 25% of split function on the side with target stricture as measured by functional renogram\n11. Kidney function ≤35% of split function on the side opposite target stricture as measured by functional renogram or other significant pathology or impairment that may impact renal function\n12. Life expectancy less than 12 months\n13. Women who are pregnant or breastfeeding\n14. Women of child-bearing potential planning to get pregnant in the next year or are unwilling to use contraception over the next 12 months\n15. Males unwilling to abstain or use protected sex for 30 days post treatment\n16. Males unwilling to use highly effective contraception for6 months post treatment if sexual partner(s) are of child-bearing potential\n17. Inability to provide legally effective informed consent\n18. Unwilling or unable to meet protocol follow-up requirements\n19. Participation in any interventional clinical investigation of a medical device, drug, or biologic (excluding registries) that may confound the results of the trial\n20. Active systemic or urinary tract infection\n21. Active malignancy in the abdomen or pelvis, or any malignancy considered considerable risk for metastasizing to the abdomen or pelvis over the next 12 months\n22. Uncontrolled diabetes defined as hemoglobin A1C ≥ 8% at baseline\n23. Unable to come off antiplatelet or anticoagulation medication prior to treatment to prevent bleeding complications at the discretion of the investigator\n24. Any other condition that may confound the results of the trial or presents an unacceptable risk for any study-related procedure\n25. Individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response\n26. Presence of any condition that precludes administration of furosemide during renograms\n27. Unable to tolerate contrast related to required study procedures or imaging.\n\nAdditional Criteria for Pharmacokinetic Substudy Inclusion Ureteric stricture measurements appropriate for treatment with a 6mm (18F) or 8mm (24F) diameter Optilume DCB Exclusion Prior treatment with any device or medical therapy that contains paclitaxel, including drug coated balloons for vascular and urethral applications","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The main objective of this clinical investigation is to assess the safety and feasibility of the Optilume DCB for treatment of ureteric strictures.",[26],"Ureteral Stricture",[28,29,30,31,32],"ureteral","ureteric","stricture","stenosis","optilume","RECRUITING","2026-03-06",{"date":36,"type":37},"2026-03-09","ACTUAL",{"date":39,"type":37},"2025-10-01",{"date":41,"type":20},"2031-07-30",{"name":43,"class":44},"Urotronic Inc.","INDUSTRY",7,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100624456","an-integrated-multi-omics-study-on-the-molecular-mechanisms-of-ureteral-stricture-100624456","NCT07409870","An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture","US-MOP","Inclusion Criteria (Ureteral Stricture Group):\n\nAge between 18 and 75 years, regardless of gender. Diagnosis of ureteral stricture confirmed by clinical symptoms and imaging (e.g., CT, IVP, or retrograde pyelography) or ureteroscopy.\n\nThe patient is scheduled for or undergoing standard clinical evaluation\u002Ftreatment for ureteral stricture.\n\nWillingness to provide stool, urine, and blood samples. Informed consent signed by the participant or their legal representative.\n\nInclusion Criteria (Healthy Control Group):\n\nAge- and sex-matched volunteers (18-75 years). No history of ureteral stricture, urinary tract obstruction, or significant renal disease.\n\nPhysical examination and laboratory tests (renal function, routine urine analysis) are within normal limits.\n\nExclusion Criteria (Applicable to Both Groups):\n\nUse of antibiotics, probiotics, prebiotics, or antifungal medications within the 4 weeks prior to sample collection.\n\nHistory of chronic gastrointestinal diseases (e.g., Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), or chronic diarrhea).\n\nKnown malignant tumors of the urinary tract or other systemic malignancies. History of major abdominal or urinary tract surgery within the last 3 months (excluding the current planned procedure for patients).\n\nPresence of severe systemic diseases, including uncontrolled diabetes, severe hepatic dysfunction, or end-stage heart failure.\n\nPregnancy or breastfeeding. Any other condition that, in the opinion of the investigator, may interfere with the microbiome or metabolomic analysis.",true,{"count":55,"type":20},120,"3 Months","OBSERVATIONAL","The goal of this observational study is to investigate the systemic pathogenesis and identify potential diagnostic biomarkers in patients with ureteral stricture and healthy volunteers. The main questions it aims to answer are:\n\nWhat are the systemic differences in the gut microbiome, urine microbiome, and metabolomic profiles (fecal, urinary, and serum) between patients with ureteral stricture and healthy controls? What are the correlations between these microbial\u002Fmetabolic alterations and clinical phenotypes, such as stricture severity, inflammatory levels, and renal function? Researchers will compare the biological panoramic profiles of patients with ureteral stricture to those of healthy controls to see if specific \"microbiome-metabolite-disease\" regulatory networks drive the development of the condition.\n\nParticipants will:\n\nProvide stool samples for gut microbiome (16S\u002FMetagenomics) and metabolomic analysis.\n\nProvide urine samples for urine microbiome and metabolomic analysis. Provide blood (serum) samples for systemic metabolomic profiling. Undergo clinical assessments, including medical history collection, imaging (e.g., CT\u002FIVP), and laboratory tests (e.g., renal function, inflammatory markers) to evaluate disease severity.",[26,60,61,62],"Ureteral Obstruction","Microbiome","Metabolomics","NOT_YET_RECRUITING","2026-02-07",{"date":66,"type":37},"2026-02-13",{"date":68,"type":20},"2026-02-01",{"date":70,"type":20},"2026-07-31",{"name":72,"class":73},"First Affiliated Hospital of Chongqing Medical University","OTHER",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":74},"100591641","application-of-the-sentire-c1000-for-ureteral-stricture-repair-100591641","NCT06983067","Application of the Sentire C1000 for Ureteral Stricture Repair","A Prospective, Open-label, Single-Arm Study Evaluating the Sentire C1000 Surgical Robotic System in Ureteral Reconstruction for Benign Ureteral Strictures","ROBUST-C1000","Inclusion Criteria:\n\n* (1) Patients aged ≥18 years and ≤80 years, male or female; (2) Patients who need to undergo upper urinary tract repair surgery; (3) Patients who are suitable for ureteral reconstruction as confirmed by the investigator; (4) Subjects who voluntarily participate in the clinical trial and agree or whose guardians agree and sign the informed consent form; (5) Willing to cooperate and complete the trial follow-up and related examinations.\n\nExclusion Criteria:\n\n* (1) Presence of severe drug\u002Fimaging contrast allergy; (2) Patients with a history of pelvic\u002Fabdominal surgery and assessed for extensive severe adhesions; (3) Those with a previous history of other malignancies and judged by the investigator to be unsuitable for enrollment; (4) Diseases that are not expected to tolerate pneumoperitoneum or prolonged head-down-foot-up position, or diseases that do not allow intraoperative positioning, such as spinal deformity or ankylosing spondylitis; (5) Those with serious comorbidities (heart, lung, liver, brain, kidney and other diseases) and those who are physically weak and cannot tolerate general anesthesia or surgery; (6) Those with serious bleeding tendency or coagulation disorders; (7) Patients who have been using anticoagulant or antiplatelet aggregating drugs for a long time, or those who have stopped using anticoagulant or antiplatelet aggregating drugs for less than 1 week before surgery (except for the prophylactic use of low molecular heparin before surgery); (8) Patients with active infectious diseases or other severe non-infectious infections; (9) Those who are positive for Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (Hepatitis B) or Hepatitis C Surface Antigen (Hepatitis C).\n\nHepatitis B Surface Antigen (HbsAg)-positive, Hepatitis C Virus (HCV)-positive, and syphilis-positive patients; (10) Persons with severe allergies, suspected or confirmed alcohol, drug or drug addiction; (11) Those with a history of epilepsy or psychosis or with cognitive impairment; (12) Women who are pregnant, breastfeeding, or planning to become pregnant during the trial, or male or female patients who do not wish to use barrier contraception during the trial; (13) Participation in any other clinical trial (except non-interventional trials) within 3 months prior to signing the informed consent form, planning to undergo any other major surgical procedure during the trial, or inability to recover from the side effects of a previous procedure; (14) Any other circumstances that the investigator considers inappropriate for participation in this clinical trial.","80 Years",{"count":85,"type":20},50,"The purpose of this clinical study is to evaluate the safety and efficacy of the Sten® Laparoendoscopic Surgical System C1000 for benign ureteral reconstruction surgery. This is a single-arm, open-label, prospective, non-randomized cohort study.\n\nEligibility criteria for recruitment to this study included how to include labeling: (1) patients aged ≥18 years and ≤80 years, male and female; (2) patients who need to undergo upper urinary tract repair surgery; (3) patients who are suitable for ureteral reconstruction surgery as confirmed by the investigator; (4) subjects voluntarily participating in the clinical trial and agreeing to, or their guardian agreeing to, and signing an informed consent form; (5) willingness to cooperate with and complete the trial follow-up and related examinations. The research subjects of this project were recruited openly, and the patients were enrolled after being informed of the study-related information, risks and benefits by the project participants and then screened to meet the enrollment criteria. A total of 50 patients will be enrolled.\n\nThe study objectives and endpoints include the following: primary endpoints: (1) the rate of surgical non-referral (2) the success rate of surgical treatment; secondary endpoints: (1) the loading time (2) the operating time of the surgeon (3) the estimated intraoperative blood loss (4) the postoperative patient's pain scores (5) the evaluation of the physiological load of the surgeon (6) the evaluation of the mental load of the surgeon (7) the rate of intraoperative transfusion (8) the duration of the hospital stay after the operation (9) the evaluation of physician satisfaction (9) the evaluation of physician's satisfaction). (9) Physician satisfaction rating (10) Overall postoperative complication rate (11) Adverse events and serious adverse events (12) Device defects (13) Postoperative readmission rate (14) Reoperation rate (15) Mortality rate.\n\nThe expected overall duration is 9 months, with an expected enrollment time of 6 months and a subject follow-up time of approximately 3 months.",[26,88],"Hydronephrosis","2025-05-13",{"date":91,"type":37},"2025-05-21",{"date":93,"type":37},"2025-05-01",{"date":95,"type":20},"2026-05-01",{"name":97,"class":73},"Xuesong Li",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":74},"100545605","duration-of-ureteral-rest-prior-to-ureteral-reconstruction-surgery-100545605","NCT06384079","Duration of Ureteral Rest Prior to Ureteral Reconstruction Surgery","Study to Assess Duration of Ureteral Rest Prior to Ureteral Reconstruction Surgery","Inclusion Criteria:\n\n* \\>18 years of age\n* Undergoing ureteral reconstruction surgery for ureteral stricture with conversion of an indwelling stent to a percutaneous nephrostomy tube for ureteral rest\n* Willing to sign informed consent form\n* Able to read and understand informed consent form\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* Inability to provide informed consent\n* Members of vulnerable patient populations",{"count":106,"type":20},25,"Our objective is to assess the effect of duration of ureteral rest, defined as time from conversion of ureteral stent to percutaneous nephrostomy, on stricture length prior to ureteral reconstruction surgery.",[26],"2024-11-22",{"date":111,"type":37},"2024-11-26",{"date":113,"type":37},"2024-09-24",{"date":115,"type":20},"2030-11",{"name":117,"class":73},"Northwestern University"]